COPZ1 mRNA levels were increased in low grade (WHO II; n = 226) and high-grade gliomas (WHO III, n = 244; WHO IV, n = 150; p < 0.0001) relative to non-neoplastic brain tissue samples (n = 4) (Fig. 1a). This evidence concerns the gene COPZ1 and central nervous system cancer.